ATE261244T1 - Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis - Google Patents

Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis

Info

Publication number
ATE261244T1
ATE261244T1 AT95943979T AT95943979T ATE261244T1 AT E261244 T1 ATE261244 T1 AT E261244T1 AT 95943979 T AT95943979 T AT 95943979T AT 95943979 T AT95943979 T AT 95943979T AT E261244 T1 ATE261244 T1 AT E261244T1
Authority
AT
Austria
Prior art keywords
amine
methyl
butene
pharmaceutical compositions
ulcerative colitis
Prior art date
Application number
AT95943979T
Other languages
English (en)
Inventor
Carr Joseph Smith
Patrick Michael Lippiello
Merouane Bencherif
William Scott Caldwell
Gary Maurice Dull
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23436979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE261244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of ATE261244T1 publication Critical patent/ATE261244T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95943979T 1995-01-06 1995-12-27 Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis ATE261244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/364,980 US5604231A (en) 1995-01-06 1995-01-06 Pharmaceutical compositions for prevention and treatment of ulcerative colitis
PCT/US1995/016901 WO1996020599A1 (en) 1995-01-06 1995-12-27 Pharmaceutical compositions for prevention and treatment of ulcerative colitis

Publications (1)

Publication Number Publication Date
ATE261244T1 true ATE261244T1 (de) 2004-03-15

Family

ID=23436979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95943979T ATE261244T1 (de) 1995-01-06 1995-12-27 Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis

Country Status (10)

Country Link
US (1) US5604231A (de)
EP (1) EP0873050B1 (de)
JP (1) JPH10512857A (de)
AT (1) ATE261244T1 (de)
AU (1) AU4529596A (de)
DE (1) DE69532687T2 (de)
DK (1) DK0873050T3 (de)
ES (1) ES2220946T3 (de)
PT (1) PT873050E (de)
WO (1) WO1996020599A1 (de)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
US20020052497A1 (en) * 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6979695B2 (en) 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6166048A (en) 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
US6531606B1 (en) * 1997-02-21 2003-03-11 Targacept, Inc. Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) * 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
US6525065B1 (en) 1997-06-30 2003-02-25 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US7214686B2 (en) * 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6624173B1 (en) 1997-06-30 2003-09-23 Targacept, Inc. Pharmaceutical compositions for treating and/or preventing CNS disorders
US5914337A (en) * 1997-08-07 1999-06-22 Virginia Commonwealth University Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
CA2321991A1 (en) * 1998-02-24 1999-09-02 Wake Forest University Method for the treatment of pain, including chronic and female specific pain
MXPA00009619A (es) 1998-04-02 2006-03-09 Targacept Inc Composiciones farmaceuticas y metodos de uso.
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US20050131034A1 (en) * 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
US6262124B1 (en) * 1998-10-22 2001-07-17 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6114382A (en) * 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2005201609B2 (en) * 1999-04-20 2007-10-18 Targacept, Inc Pharmaceutical compositions for inhibition of cytokine production and secretion
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
EP1185514A1 (de) * 1999-06-07 2002-03-13 Targacept, Inc. Pharmaceutische zusammensetzungen und verwendungsmethode
US6890935B2 (en) * 1999-11-01 2005-05-10 Targacept, Inc. Pharmaceutical compositions and methods for use
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) * 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6689788B1 (en) * 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
HUP0501017A3 (en) * 2001-12-14 2010-06-28 Targacept Methods and compositions for treatment of central nervous system disorders
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
JP2005522457A (ja) * 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害
DK1519939T5 (da) 2002-07-05 2011-01-24 Targacept Inc N-Aryl-diazaspirocykliske forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2005037832A2 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
JP2007530586A (ja) * 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
ES2330849T3 (es) * 2004-04-02 2009-12-16 Arterial Remodelling Technologies Inc. Ensamblaje de stent basado en polimero.
CN101044134A (zh) * 2004-09-20 2007-09-26 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
US7732607B2 (en) * 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CL2007002684A1 (es) * 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
DK2107920T3 (da) 2007-01-29 2013-10-21 Univ Fraser Simon Transvaskulært nervestimulationsapparat
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
CA2680477A1 (en) * 2007-03-13 2008-09-18 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
TW200845977A (en) * 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
JP2010535237A (ja) * 2007-07-31 2010-11-18 ターガセプト・インコーポレイテッド （２ｓ）−（４ｅ）−ｎ−メチル−５−（３−（５−イソプロポキシピリジン）イル）−４−ペンテン−２−アミンの経皮投与
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009046025A1 (en) * 2007-10-01 2009-04-09 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
EP2242364A4 (de) * 2008-01-15 2011-09-21 Targacept Inc Zubereitung und enantiomere trennung von 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonan und neue salzformen des racemats und der enantiomere
JP2011513421A (ja) * 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US8412338B2 (en) * 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
WO2010065443A1 (en) 2008-12-01 2010-06-10 Targacept, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US8802694B2 (en) 2009-12-07 2014-08-12 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetycholine receptor ligands
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法
MX337106B (es) 2010-05-27 2016-02-12 Targacept Inc Antagonistas no competitivos de receptores nicotinicos.
WO2012125518A1 (en) 2011-03-14 2012-09-20 Targacept, Inc. Salt forms of 3 - cyclopropylcarbonyl - 3, 6 - diazabicyclo [3.1.1] heptane
WO2012129262A1 (en) 2011-03-23 2012-09-27 Targacept, Inc. Treatment of attention deficit/hyperactivity disease
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
TW201311698A (zh) 2011-08-22 2013-03-16 Targacept Inc 作為神經元菸鹼乙醯膽鹼受體配位體之１，４－二氮雜雙環［３．２．２］壬烷
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
AU2013230648B2 (en) 2012-03-05 2017-06-15 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus and methods
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
BR112014032002A2 (pt) 2012-06-21 2017-06-27 Univ Fraser Simon sistemas de estimulação de diafragma transvascular e métodos de utilização
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
CA2930809A1 (en) 2013-11-22 2015-05-28 Simon Fraser University Apparatus and methods for assisted breathing by transvascular nerve stimulation
EP3824949B1 (de) 2014-01-21 2023-12-20 Lungpacer Medical Inc. Systeme zur optimierung der multi-elektroden-nervenstimulation
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン，エルエルシー アルファ７−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405107B1 (de) 2016-01-20 2023-04-12 Setpoint Medical Corporation Steuerung der vagalstimulierung
EP3405255B1 (de) 2016-01-20 2025-12-31 Setpoint Medical Corporation Implantierbare mikrostimulatoren und induktive ladesysteme
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
US12029901B2 (en) 2017-06-30 2024-07-09 Lungpacer Medical Inc. Devices and methods for prevention, moderation, and/or treatment of cognitive injury
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US20190175908A1 (en) 2017-12-11 2019-06-13 Lungpacer Medical Inc. Systems and methods for strengthening a respiratory muscle
CN112384504A (zh) 2018-06-15 2021-02-19 R.J.雷诺兹烟草公司 烟碱的纯化
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020097331A1 (en) 2018-11-08 2020-05-14 Lungpacer Medical Inc. Stimulation systems and related user interfaces
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
WO2020232333A1 (en) 2019-05-16 2020-11-19 Lungpacer Medical Inc. Systems and methods for sensing and stimulation
EP3983057B1 (de) 2019-06-12 2026-04-08 Lungpacer Medical Inc. Schaltung für medizinische stimulationssysteme
JP2023512447A (ja) 2020-01-13 2023-03-27 ザ ファインスタイン インスティチューツ フォー メディカル リサーチ 脾臓への高密度集束超音波刺激による出血及び出血性疾患の治療
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639418A1 (de) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
CA1337549C (en) * 1989-06-08 1995-11-14 Hakan Ahlman Method for the treatment of ulcerative proctitis and colitis
JPH0334929A (ja) * 1989-06-29 1991-02-14 Teikoku Seiyaku Kk 潰瘍性大腸炎およびクローン病治療用経口投与用組成物
CA2025398A1 (en) * 1989-09-20 1992-03-15 Timothy Gerard Dinan Diagnosis and treatment of a disorder of the gastrointestinal tract
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5340801A (en) * 1991-05-08 1994-08-23 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having cholecystokinin and gastrin antagonistic properties
US5356919A (en) * 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
JPH05262747A (ja) * 1991-10-17 1993-10-12 Morishita Roussel Kk 潰瘍性大腸炎治療剤
EP0647136B1 (de) * 1992-06-22 1997-03-19 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verwendung von kondensierte bis-(3,4-dihydro-pyridinyl)methane zur behandlung von morbus crohn, colitis ulcerosa, chronisch inflammatorischen prozessen und als antiproliferative mitteln

Also Published As

Publication number Publication date
EP0873050A4 (de) 1999-09-22
WO1996020599A1 (en) 1996-07-11
AU4529596A (en) 1996-07-24
US5604231A (en) 1997-02-18
PT873050E (pt) 2004-06-30
DE69532687D1 (de) 2004-04-15
JPH10512857A (ja) 1998-12-08
EP0873050A1 (de) 1998-10-28
DK0873050T3 (da) 2004-05-03
ES2220946T3 (es) 2004-12-16
DE69532687T2 (de) 2005-03-03
EP0873050B1 (de) 2004-03-10

Similar Documents

Publication Publication Date Title
ATE261244T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung der ulzerativen kolitis
ATE250590T1 (de) Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems
BG101841A (bg) Инхибитори на клетъчна адхезия
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE602004030222D1 (de) 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
NL300175I1 (nl) Methylsulfonylfenyl-2-(5H)-furanonen als remmers van COX-2.
LV12209A (lv) Ar fenilgrupu aizvietoti heterocikli ka ciklooksigenazes-2 inhibitori
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE368031T1 (de) Neue gamma secretase inhibitoren
GEP20053530B (en) Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE212343T1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
DE602004003806D1 (de) 1-(2H-PYRAZOL-3-YL)-3-ä4-Ä1-(BENZOYL)-PIPERIDIN-4-YLMETHYLÜ-PHENYLü-HARNSTOFFDERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER P38 KINASE UND/ODER DES TNF ZUR BEHANDLUNG VON ENTZÜNDUNGEN
ATE339205T1 (de) (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR0113011A (pt) Novos compostos e sua utilização como inibidores de transporte de glicina; composição farmacêutica e método do tratamento
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE60332860D1 (de) Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
ATE172118T1 (de) Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
BR0010338A (pt) Composto enanciomericamente enriquecido, composição farmacêutica, método para tratar uma doença ou condição mediada por cck-a, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0873050

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked
RZN Patent revoked